Cellectis Q2 2024 Adj EPS $(0.24) Beats $(0.30) Estimate
Portfolio Pulse from Benzinga Newsdesk
Cellectis (NASDAQ:CLLS) reported a Q2 2024 adjusted EPS of $(0.24), beating the analyst consensus estimate of $(0.30) by 20%.
August 06, 2024 | 9:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cellectis reported a Q2 2024 adjusted EPS of $(0.24), which is better than the analyst consensus estimate of $(0.30). This positive earnings surprise could boost investor confidence and potentially lead to a short-term increase in the stock price.
The better-than-expected EPS indicates that the company is performing better than analysts anticipated, which is generally a positive signal for investors. This could lead to increased buying interest and a short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100